RESUMO
Amyloid ß oligomers (Aßo) are the main toxic species in Alzheimer's disease, which have been targeted for single drug treatment with very little success. In this work we report a new approach for identifying functional Aßo binding compounds. A tailored library of 971 fluorine containing compounds was selected by a computational method, developed to generate molecular diversity. These compounds were screened for Aßo binding by a combined 19F and STD NMR technique. Six hits were evaluated in three parallel biochemical and functional assays. Two compounds disrupted Aßo binding to its receptor PrPC in HEK293 cells. They reduced the pFyn levels triggered by Aßo treatment in neuroprogenitor cells derived from human induced pluripotent stem cells (hiPSC). Inhibitory effects on pTau production in cortical neurons derived from hiPSC were also observed. These drug-like compounds connect three of the pillars in Alzheimer's disease pathology, i.e. prion, Aß and Tau, affecting three different pathways through specific binding to Aßo and are, indeed, promising candidates for further development.
RESUMO
The synthesis of two new Ir(III) â complexes which are effectively isostructural with well-established [Ru(NN)2(dppz)](2+) systems is reported (dppz=dipyridophenazine; NN=2,2'-bipyridyl, or 1,10-phenanthroline). One of these Ir(III) complexes is tricationic and has a conventional N6 coordination sphere. The second dicationic complex has a N5Câ coordination sphere, incorporating a cyclometalated analogue of the dppzâ ligand. Both complexes show good water solubility. Experimental and computational studies show that the photoexcited states of the two complexes are very different from each other and also differ from their Ru(II) analogues. Both of the complexes bind to duplex DNA with affinities that are two orders of magnitude higher than previously reported Ir(dppz)-based systems and are comparable with Ru(II)(dppz) analogues.